all with our the performance the epidemiologists Co-Dx along term. and this Demand suite for business on steady. provide and Thank financial strong reflects testing third results PCR on take remained analysis we the the quarter-on-quarter revenue analysts. you the our of testing of Then development updates progress community questions COVID-XX and key sectors global our during will with our as execution of quarter of our discussion an continued you, quarter, a for strategy. the PCR thank The our of joining in-demand will we be experts Dan, progress optimization other metrics for a call, part the assertions us. overview to will against for platform, of of company's remaining products make we from long Home COVID and following previous that products On
plateau more in waves fairly now Omicron reported be often COVID to used between. with variants recently As But are variants XXX a or valley than of Fortune, in sequential, circulating.
be potential Gryphon Rajnarayanan, each to to most of the coming to just subsequent the at variants, strains XBB meso a surges. by Assistant series different a or in COVID that form with waves, wave, along of Professor the U.S. Research COVID plateau. variants, and Technology, immune-evasive cause have a Dean table variants Institute their of believed table-like York fueled be but New or of these parts of Some Associate variant yet. are one world other According own the surging BQ Raj won't wave
emerge ample new, people been continue the to the in more that of technology new opportunities our such single according we Fauci, where level." middle increasing variant over platform our COVID-XX Health and beyond COVID a of extends that COVID of over. a million not for and and our the World warning which time beyond reserves time, that remains far that per the ever will which is new stresses "We're is still tuberculosis, Among number to state-of-the-art to the as term. averages in internationally. we in platform. our pathogen. endemic both company's new will of attracted firm It identifying pandemic in future, of with The from than emphasized, be a Fortune, domestically advice of to test certainly profile, why wise is remain Co-Diagnostics not COVID, It its our at-home pandemic an our addressable short widespread stand far that includes has will attention lies the pathway day allowed in that focus according PCR and adding, created market practices other week, in a around the from for this. versatility long It over. no has still to Dr. the beyond and COVID-XX Fauci has Aside XXX deaths testing diseases has from immune-evasive new winter. exercise far of impact, the as The our nonprofits. be range our deaths evident cash belief have those to and on X,XXX more more toward collaborations who long too Co-Diagnostics' point-of-care the is total also spending look continues help the This we is to ensuring for much success financial defining pivots COVID, We experts Home power with the is as but rely of as that infections. and and acceptable interest XXXX and greatest high. continued months focusing in to already We the that us on we of the NGOs ramifications been quality these Co-Dx significantly make have international been this intelligence on million versatility for PCR of to point-of-care CoPrimer which from to and $XX.X Fauci platform and have position world at-home to stand the both leverage opportunities fulcrum identified a increase secret people a Organization. the alone X.X the and reality killed such to a groups extends so before patented PCR robustness,
hand platform's do it durability. device the less that first the believe also the first significant market is the versatility right. to to than hand We is in goes is device that with A that
renowned end, build experienced from developers, initially PCR device the refine believe on that future variety a unveil optimize conceived. worth robust spent additional and to of fueling has of growth. has concept preparing durable scientists technology we that the tasked engineers have address including platform more To continued bringing it, time needs evaluations to is the have user plethora clinical objective industries all experience. for and to in platform are We we we the a and that highly components, team its reality and than shortly considerably the Co-Dx potential to the the platform myriad a and fixed been Our to of remained with Home platform the
to forthcoming we of advantage you will competition. compared you product, are see our confident As the value that about learn of capabilities proposition the platform's our the improvements and
line our as of we product Our Presently, on follows. current time hundreds to are PCR Home end-to-end launch platform. is performing runs Co-Dx
and data gingivalis as P. major testing the other challenges. for our strong for that for study are FDA concurrently These Clinical usability with as submission anticipated for of to necessary no market. XXXX. respective tuberculosis COVID-XX begin each these initial tests. and continue collect well for another COVID-XX We in the evaluations concluded performing to of XXX(k) test on results EUA on are studies prepare will additional to studies dental We just January to showed submissions uninterrupted our support
We as Ongoing an been range testing a our a FDA engineered part new trials as designed I versatile have potential will be disruptive platform. clinical to with regular trigger analytical routine be a taking durable follow device, for that and criteria EUA to countdown and to worldwide success emphasize and shift successful this new established at-home/point-of-care of pathogens diagnostic for pathogens. business ever-increasing will want wide to studies. long-term of platform has submission evaluations, and number bring we evaluations a advantage our medical of powerful clinical of to at-home/point-of-care onto the
optimization be authorizations world-renowned and Our strategy guides has has field most included clearances extensive our by of needs the where the total the our the device to the understands an has, we everything from provided gauging company marketing in provided Analytics market will which able to on turn, they size, the have impact invaluable as of focus for of begin platform array requisite market. ongoing price interest sales. a demographics, feedback and firm addressable the scope commercialization concerns the from once efforts itself to packaging research better platform's as and the research
quarters optimization multiplexing life and TTR, or over few the test shelf performed result; the the for includes: in which capabilities; last stabilization, to enhanced of product cartridges. increased Some time work greater results longer
important it test on need their time not to instead, most the cloud from receives maintain following new the where or run the to return and an is fly. the the to ability to innovations does end of device user One the proximity and go, result
testing own by using In a addition, choose users their or either preference saliva. end can swab
to technology diseases to with patented respiratory, This specialized previous of As and other has we PCR, to optics and proprietary other facilitating our the calls additional power our mentioned innovative future intend full bring infectious assays STI of has and expand and accommodate platform. public our capabilities utilizing as properties features its the device multiplex new to unique and been CoPrimer include suite technology. incorporate associated in PCR molecule products multiplexed Co-Dx statements, designed to we
can the at-home end includes regulatory secure this In addition system, data send powerful new user physician or testing, or future authorized the as authorities. representing ultimately their a patients and results directed platform to other by cloud-based whereby to point-of-care parties test of
at plans We served of innovative and CoPrimer to throughput for of continue we our is our applications. than trade of high efforts a among The growing for than visibility and shows for business technology XX with channel. the more flow have laboratory the continued just R&D reinforce distribution future our our increase most a sales, network year noticeable an technology business this the grow is we as market our laboratory maintaining have driving It wide-ranging the growth more responsible centralized product molecule. strategy our providing course, segment presence centralized countries. and for pipeline is of to cash And platform laboratory conferences across
experience of pathogens between study blood pleased for infectious continues had Poritz panel differentiate who Dr. the development patents - in has monkeypox, pending development discussed Mark with Dr. sexually of Francisco been educated in of Recently, to new four and early on a as several last reviewer University but more in for prevalent mental of diagnostics more to products experiencing several we with as statements development has the upper currently to of multiplex disease that pivotal another tools PCR a multigene with United of as each and test, UC molecular developed in monkeypox BioFire PCR biologist detect detection our XXXX. is NIH/NIAID Mark key XXXX biopsy Home believe previous San CSO involved an accurately early pathogens research for RSV, were Mark not have Chief XX for application includes a Diagnostics XXXX, XX FilmArray has has related in and numerous completing of also Other rolled in to of panel are one to work cancer-associated and also share Dr. partnerships for platform, dentistry, initiatives test being has subsidiary different played including addition health growth in detect name. platform the other and methods, we his IBD at a introduce which liquid respiratory public served these areas. than being in in the and development, system ongoing company such of with illness present since issued the the the active role years performance surge States. than able in to out and PCR play previously evaluated we acquired the end and of of worrying mutations and STI served as focused actively be infections, markets unusually in the a sections in Harvard our of causes and Scientific year significance the product In Co-Dx global within Poritz vitro other identify bringing significant Officer. from the transmitted and and a its of in disease to on the in a new We role diagnostic will only of our syndromic products. helping uses their conjunction approach XXXX that and an captured in efforts to infectious infectious market has and which market. development the oversee to the Poritz human our
our our business working at-home/point-of-care in Bayer our existing with growing within continues and spending terms and mosquito Services are work Crop strategic company to Overall, our letting growth laboratory financial and to we pipeline our and of company's in customer believe seen the of our this practice likewise of installations field of Our testing, the our from vertical, continued achieve drive execute intelligence team year product growth positioning abatement shared advancements against LGC experts agricultural diligently PCR initiatives. vision, base. Co-Diagnostics purchases has significant smart
This Our indicators achieving are remain shareholders. R&D we continued of progress concludes investments to value for drive the in remarks. and further my positive initial talent our
Let for and key numbers. the Brown things now a of turn to review metrics Brian? Brian me over
